Castle Biosciences, Inc. (CSTL) shares ended the last trading session 9.4% higher at $34.26. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.4% gain over the past four weeks. The stock rallied as optimism grew over the company's promising portfolio that consists of tests for skin cancers, Barrett's esophagus, mental health conditions and uveal melanoma. This company is expected to post quarterly loss of $0.08 per ...